ARS Pharmaceuticals’ (SPRY) “Outperform” Rating Reaffirmed at William Blair

William Blair reaffirmed their outperform rating on shares of ARS Pharmaceuticals (NASDAQ:SPRY) in a research note released on Monday,RTT News reports.

SPRY has been the topic of several other research reports. Oppenheimer began coverage on shares of ARS Pharmaceuticals in a research note on Monday, February 10th. They set an “outperform” rating and a $40.00 target price on the stock. Raymond James upped their target price on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a research note on Tuesday, January 14th. Finally, Leerink Partners upped their target price on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, ARS Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $28.80.

ARS Pharmaceuticals Price Performance

Shares of ARS Pharmaceuticals stock opened at $10.18 on Monday. The stock has a market cap of $989.34 million, a price-to-earnings ratio of -19.96 and a beta of 0.99. The firm’s 50-day moving average is $11.91 and its 200 day moving average is $13.21. ARS Pharmaceuticals has a 1 year low of $7.55 and a 1 year high of $18.51.

Insider Activity

In other news, Director Laura Shawver sold 14,772 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $13.75, for a total transaction of $203,115.00. Following the completion of the transaction, the director now directly owns 210,346 shares in the company, valued at approximately $2,892,257.50. This represents a 6.56 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Sarina Tanimoto sold 100,000 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $13.16, for a total value of $1,316,000.00. Following the transaction, the insider now owns 1,148,499 shares of the company’s stock, valued at $15,114,246.84. This represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 417,044 shares of company stock valued at $5,204,515 in the last quarter. 40.10% of the stock is currently owned by insiders.

Institutional Trading of ARS Pharmaceuticals

A number of institutional investors have recently bought and sold shares of SPRY. Creative Planning lifted its position in ARS Pharmaceuticals by 7.0% in the third quarter. Creative Planning now owns 35,263 shares of the company’s stock worth $511,000 after buying an additional 2,307 shares during the last quarter. Raymond James & Associates bought a new stake in ARS Pharmaceuticals in the third quarter worth $2,969,000. Wealth Enhancement Advisory Services LLC lifted its position in ARS Pharmaceuticals by 9.1% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 57,624 shares of the company’s stock worth $836,000 after buying an additional 4,810 shares during the last quarter. US Bancorp DE lifted its position in ARS Pharmaceuticals by 11,951.6% in the third quarter. US Bancorp DE now owns 18,680 shares of the company’s stock worth $271,000 after buying an additional 18,525 shares during the last quarter. Finally, GSA Capital Partners LLP increased its stake in ARS Pharmaceuticals by 67.7% in the third quarter. GSA Capital Partners LLP now owns 98,900 shares of the company’s stock worth $1,434,000 after purchasing an additional 39,921 shares during the period. 68.16% of the stock is currently owned by institutional investors.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.